

AGIOS PHARMACEUTICALS INC

Form 8-K

December 08, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 7, 2014**

**Agios Pharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**001-36014**  
**(Commission**

**File Number)**

**26-0662915**  
**(IRS Employer**

**Identification No.)**

**38 Sidney Street, 2<sup>nd</sup> Floor, Cambridge, MA**

**02139**

**(Address of Principal Executive Offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (617) 649-8600**

**Not applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On December 7, 2014, Agios Pharmaceuticals, Inc. ( the Company ) issued a press release announcing new phase 1 data on AG-221, its first-in-class inhibitor of IDH2 mutations in patients with advanced hematologic malignancies, including acute myeloid leukemia. On December 8, 2014, the Company issued a press release announcing first clinical data from its Phase 1 single (SAD) and multiple ascending dose (MAD) clinical trials of AG-348, its first-in-class oral activator of pyruvate kinase-R for the treatment of pyruvate kinase deficiency, a cause of hemolytic anemia, in healthy volunteers. The Company presented both data at the 2014 American Society of Hematology Annual Meeting and Exposition held on December 6 - 9, 2014. The full text of the press releases issued in connection with this announcement is attached as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit

No.	Description
99.1	Press release issued by Agios Pharmaceuticals, Inc. on December 7, 2014.
99.2	Press release issued by Agios Pharmaceuticals, Inc. on December 8, 2014.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AGIOS PHARMACEUTICALS, INC.**

Date: December 8, 2014

By: /s/ David P. Schenkein, M.D.  
David P. Schenkein, M.D.

Chief Executive Officer

**EXHIBIT INDEX**

Exhibit No.	Description
99.1	Press release issued by Agios Pharmaceuticals, Inc. on December 7, 2014.
99.2	Press release issued by Agios Pharmaceuticals, Inc. on December 8, 2014.